HOOKIPA PHARMA INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei HOOKIPA PHARMA INC listata cu simbolul US.HOOK ==Descriere companie== HOOKIPA Pharma Inc.(https://www.hookipapharma.com/) is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candida...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei HOOKIPA PHARMA INC listata cu simbolul US.HOOK | Pagina dedicata companiei HOOKIPA [[PHARMA]] INC listata cu simbolul US.HOOK | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 1 octombrie 2024 09:24
Pagina dedicata companiei HOOKIPA PHARMA INC listata cu simbolul US.HOOK
Descriere companie[edit | ]
HOOKIPA Pharma Inc.(https://www.hookipapharma.com/) is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.
Grafic actiuni companie[edit | ]